Abstract: Methods and systems of the present invention generally relate to questionnaires and diagnostic algorithms. Features and principles of the present invention may include a method of generating a diagnostic algorithm. The method may involve receiving information reflecting a plurality of individuals' answers to questions, performing an analysis on the received information to generate a synthetic variable, and generating a diagnostic algorithm from at least the synthetic variable using a tree segmentation technique.

Abstract: The present invention concerns a molecular signature of cutaneous pigmentary spots, comprising the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7, SOSTDC1, FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 and ACTN1, and various applications of this signature. In particular, the invention concerns a method for characterizing a known or suspected pigmentary spot in a human being, comprising comparing the levels of expression in skin samples obtained from said spot and from adjacent undamaged skin, of at least one dermal gene linked to the extracellular matrix selected from the list constituted by the genes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7, SOSTDC1, FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 and ACTN1.

Abstract: The present invention concerns a molecular signature of cutaneous pigmentary spots, comprising the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2, and various applications of this signature. In particular, the invention concerns a method for characterizing a known or suspected pigmentary spot in a human being, comprising comparing the levels of expression in skin samples obtained from said spot and from adjacent undamaged skin, of at least one dermal gene linked to matrix remodelling or to its extracellular proteoglycan and glycoprotein components, selected from the list constituted by the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2. The invention also concerns methods for evaluating the efficacy of a pigmentary spot treatment, cosmetic and therapeutic methods for the treatment of pigmentary spots, and various modulators for said genes, and their use.

Abstract: The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXL?, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXL?, said part comprising at least 18 nucleotides. The invention also concerns methods for screening molecules modulating the expression of a gene coding for BNIPXL-beta and molecules modulating the activity of the BNIPXL-beta polypeptide, in order to identify an agent for use for cosmetic or therapeutic purposes in the field of pigmentation. The invention also encompasses various uses of molecules which may be identified by these methods.

Abstract: The invention relates to new non-therapeutic methods allowing the level of skin neurosensitivity and/or the state of neurosensorial skin reactivity of an individual to be evaluated by applying a peripheral nervous system stimulant to one skin area, the method being implemented under conditions of safety and comfort acceptable for the user, irrespective of his or her skin type.

Abstract: The present invention relates to the field of preventive and/or curative protection of delicate lips. More precisely, a subject-matter of the invention is the cosmetic use of active principles which are capable of enhancing the content of ceramides in the lips, such as a ceramide precursor comprising a 6-hydroxy-4-sphingenine base, ascorbic acid or one of its analogues, as protective agent for delicate lips. The invention is additionally targeted at corresponding compositions for labial application.

Abstract: The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXL?, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXL?, said part comprising at least 18 nucleotides. The invention also concerns methods for screening molecules modulating the expression of a gene coding for BNIPXL-beta and molecules modulating the activity of the BNIPXL-beta polypeptide, in order to identify an agent for use for cosmetic or therapeutic purposes in the field of pigmentation. The invention also encompasses various uses of molecules which may be identified by these methods.

Abstract: The invention provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 9 selected from the group consisting of the FREQ, NT_030046.18, NT_030046.17, GTF3C5, CEL, CELL, FS, ABO, BARBLI, DDX31, GTF3C4 and Q96MA6 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 6 selected from the HLAG, NT_007592.445, NT_007592.446, NT_007592.506, NT_007592.507, NT_007592.508, HSPA1 B, G8, NEU1, NG22, BAT8, HLA-DMB, HLA-DMA, BRD2, HLA-DQA1, HLA-DQA2, NT_007592.588, GRM4, RNF23, FLJ22638, NT_007592.459 and NT_007592.457 genes, and diagnostic methods employing same.

Abstract: Methods and kits for diagnosing a predisposition to premature canities in an individual are disclosed. A method for diagnosing a predisposition to premature canities in an individual comprises detecting at least one SNP marker of the human chromosome 9, selected from the group consisting of rs306534, rs3739902, rs575916, and rs365297. A kit for diagnosing a predisposition to premature canities comprises a means for detecting in a sample of human genetic material, the allele of a SNP marker of the human chromosome 9 selected from the markers rs306534, rs3739902, rs575916 and rs365297; and a positive or negative control.

Abstract: Use of a cosmetic and/or dermatological and/or hygiene composition containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of sensitive or intolerant skin.

Abstract: The present invention relates to the field of preventive and/or curative protection of delicate lips. More precisely, a subject-matter of the invention is the cosmetic use of active principles which are capable of enhancing the content of ceramides in the lips, such as a ceramide precursor comprising a 6-hydroxy-4-sphingenine base, ascorbic acid or one of its analogues, as protective agent for delicate lips. The invention is additionally targeted at corresponding compositions for labial application.

Abstract: One aspect of the present invention relates to methods of generating a profile data set. In an exemplary embodiment, data is accessed and the accessed data is processed using a dynamic cluster method, mobile center method, and/or a k-means algorithm, each using neighborhood data. Other aspects relate to methods of generating a diagnosis, advice, and/or other information. Further aspects relate to dynamic surveying and systems.

Abstract: The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for the skin, in particular in the treatment of pigmentation marks, and as a pro-pigmenting agent for superficial body growths.

Abstract: One aspect of the present invention relates to methods of generating a profile data set. In an exemplary embodiment, data is accessed and the accessed data is processed using a dynamic cluster method, mobile center method, and/or a k-means algorithm, each using neighborhood data. Other aspects relate to methods of generating a diagnosis, advice, and/or other information. Further aspects relate to dynamic surveying and systems.

Abstract: The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for the skin, in particular in the treatment of pigmentation marks, and as a pro-pigmenting agent for superficial body growths.

Abstract: Methods and kits for diagnosing a predisposition to premature canities in an individual are disclosed. A method for diagnosing a predisposition to premature canities in an individual comprises detecting at least one SNP marker of the human chromosome 9, selected from the group consisting of rs306534, rs3739902, rs575916, and rs365297. A kit for diagnosing a predisposition to premature canities comprises a means for detecting in a sample of human genetic material, the allele of a SNP marker of the human chromosome 9 selected from the markers rs306534, rs3739902, rs575916 and rs365297; and a positive or negative control.

Abstract: The disclosure provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 3 selected from KIAA1042, CCK, CACNA1D, ARHGEF3 and AL133097 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 5 selected from the KLHL3, HNRPA0, CDC25C, EGR1, C5orf7, LOC51308, ETF1, HSPA9B, PDCHA1 to PDCHA13, CSF1R, RPL7, PDGFRB, TCOF1, AL133039, CD74, RPS14, NDST1, G3BP, GLRA1, C5orf3, MFAP3, GALNT10 and FLJ117151 genes, or the sequence of which corresponds to all or part of a gene or human chromosome 11 selected from the GUCY1A2, CUL5, ACAT1, NPAT, ATM, AF035326, AF035327m A0035328m BC029536, FLJ20535, DRD2, ENS303941, IGSF4, LOC1092, BC010946, TAGLN, PCSK7 and ENS300650 genes, and diagnostic methods employing same.

Abstract: Methods and systems for diagnosing and quantifying a degree of severity of hair loss. In accordance with one implementation, a method is provided that includes the steps of determining a client's gender, presenting to the client a first set of gender-tailored questions for diagnosing hair loss, and determining whether the client suffers from (a) significant hair loss or (b) less significant hair loss based on the client's answers to the first set of questions. If the client is determined to suffer from significant hair loss, the client is diagnosed with severe hair loss. Alternatively, the method proceeds to the steps of presenting to the client a second set of gender-tailored questions for diagnosing hair loss, and determining whether the client suffers from (c) moderate hair loss or (d) slight hair loss based on the client's answers to the second set of questions.

Abstract: Methods and systems of the present invention generally relate to questionnaires and diagnostic algorithms. Features and principles of the present invention may include a method of generating a diagnostic algorithm. The method may involve receiving information reflecting a plurality of individuals' answers to questions, performing an analysis on the received information to generate a synthetic variable, and generating a diagnostic algorithm from at least the synthetic variable using a tree segmentation technique.

Abstract: The invention provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 9 selected from the group consisting of the FREQ, NT_030046.18, NT_030046.17, GTF3C5, CEL, CELL, FS, ABO, BARHL1, DDX31, GTF3C4 and Q96MA6 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 6 selected from the HLAG, NT_007592.445, NT_007592.446, NT_007592.506, NT_007592.507, NT_007592.508, HSPA1B, G8, NEU1, NG22, BAT8, HLA-DMB, HLA-DMA, BRD2, HLA-DQA1, HLA-DQA2, NT_007592.588, GRM4, RNF23, FLJ22638, NT_007592.459 and NT_007592.457 genes, and diagnostic methods employing same.